

# Michele Fornaro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7011621/publications.pdf>

Version: 2024-02-01

188  
papers

7,738  
citations

57758

44  
h-index

71685

76  
g-index

192  
all docs

192  
docs citations

192  
times ranked

9838  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacotherapy to prevent the onset of depression following traumatic brain injury. Expert Opinion on Pharmacotherapy, 2022, 23, 255-262.	1.8	1
2	Melatonin and melatoninâ€•agonists for metabolic syndrome components in patients treated with antipsychotics: A systematic review and metaâ€•analysis. Human Psychopharmacology, 2022, 37, e2821.	1.5	5
3	The prevalence, odds, predictors, and management of tobacco use disorder or nicotine dependence among people with severe mental illness: Systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2022, 132, 289-303.	6.1	24
4	Neurological, Psychiatric, and Psychological Implications of the COVID-19 Pandemic: Protocol for a Large-Scale Umbrella Review of Observational Studies. International Journal of Environmental Research and Public Health, 2022, 19, 1681.	2.6	1
5	Previous Functional Social and Behavioral Rhythms Affect Resilience to Covid-19-Related Stress among Old Adults. Journal of Public Health Research, 2022, 11, jphr.2022.2768.	1.2	9
6	Machine Learning Prediction of Comorbid Substance Use Disorders among People with Bipolar Disorder. Journal of Clinical Medicine, 2022, 11, 3935.	2.4	7
7	Psychological distress in patients with serious mental illness during the COVID-19 outbreak and one-month mass quarantine in Italy. Psychological Medicine, 2021, 51, 1054-1056.	4.5	104
8	The prevalence, odds and predictors of lifespan comorbid eating disorder among people with a primary diagnosis of bipolar disorders, and vice-versa: Systematic review and meta-analysis. Journal of Affective Disorders, 2021, 280, 409-431.	4.1	28
9	Case of aripiprazole longâ€•actingâ€•related akathisia successfully managed with carvedilol: A case report. Psychiatry and Clinical Neurosciences, 2021, 75, 114-115.	1.8	2
10	Clinical features associated with early drop-out among outpatients with unipolar and bipolar depression. Journal of Psychiatric Research, 2021, 136, 522-528.	3.1	5
11	Is there a biosignature for lithium response in bipolar disorder? Evidence and implications. , 2021, , 365-372.		0
12	There are no â€•sideâ€•effects, just â€•coreâ€•effects of antipsychotic pharmacotherapy. Acta Psychiatrica Scandinavica, 2021, 143, 99-100.	4.5	0
13	â€•Novel Psychopharmacology for Depressive Disordersâ€• Advances in Experimental Medicine and Biology, 2021, 1305, 449-461.	1.6	12
14	Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases. Clinical Psychopharmacology and Neuroscience, 2021, 19, 174-178.	2.0	28
15	How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. Revista Brasileira De Psiquiatria, 2021, 43, 189-202.	1.7	32
16	Gut Microbiota and Bipolar Disorder: An Overview on a Novel Biomarker for Diagnosis and Treatment. International Journal of Molecular Sciences, 2021, 22, 3723.	4.1	31
17	In Memory of Hagop Akiskal. Clinical Practice and Epidemiology in Mental Health, 2021, 17, 48-51.	1.2	9
18	Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. World Psychiatry, 2021, 20, 244-275.	10.4	76

#	ARTICLE	IF	CITATIONS
19	Suicide and Genetic Biomarkers: Toward Personalized Tailored-treatment with Lithium and Clozapine. <i>Current Pharmaceutical Design</i> , 2021, 27, 3293-3304.	1.9	13
20	Peripheral levels of C-reactive protein, tumor necrosis factor- $\alpha$ , interleukin-6, and interleukin-1 $\beta$ across the mood spectrum in bipolar disorder: A meta-analysis of mean differences and variability. <i>Brain, Behavior, and Immunity</i> , 2021, 97, 193-203.	4.1	80
21	Cancer diagnosis and suicide outcomes: Umbrella review and methodological considerations. <i>Journal of Affective Disorders</i> , 2021, 295, 1201-1214.	4.1	17
22	Implications of the COVID-19 pandemic for people with bipolar disorders: A scoping review. <i>Journal of Affective Disorders</i> , 2021, 295, 740-751.	4.1	33
23	Trazodone Add-on in COVID-19-related Selective Serotonin Reuptake Inhibitor-resistant Post-traumatic Stress Disorder in Healthcare Workers: Two Case Reports. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 780-785.	2.0	12
24	Novel experimental and early investigational drugs for the treatment of bipolar disorder. <i>Expert Opinion on Investigational Drugs</i> , 2021, , 1-7.	4.1	1
25	Role and Perspectives of Inflammation and C-Reactive Protein (CRP) in Psychosis: An Economic and Widespread Tool for Assessing the Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13032.	4.1	10
26	Suicide in Healthcare Workers: Determinants, Challenges, and the Impact of COVID-19. <i>Frontiers in Psychiatry</i> , 2021, 12, 792925.	2.6	47
27	The effect of paliperidone palmitate long-acting injectable (PP-LAI) on "non-core" symptoms of schizophrenia: a retrospective, collaborative, multicenter study in the "real world" everyday clinical practice. <i>Rivista Di Psichiatria</i> , 2021, 56, 143-148.	0.6	2
28	Network analysis of the relationship between depressive symptoms, demographics, nutrition, quality of life and medical condition factors in the Osteoarthritis Initiative database cohort of elderly North-American adults with or at risk for osteoarthritis. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e14.	3.9	20
29	Prevalence and correlates of major depressive disorder, bipolar disorder and schizophrenia among nursing home residents without dementia: systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2020, 216, 6-15.	2.8	17
30	Lithium Exposure During Pregnancy and the Postpartum Period: A Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. <i>American Journal of Psychiatry</i> , 2020, 177, 76-92.	7.2	83
31	Alexithymia, resilience, somatic sensations and their relationships with suicide ideation in drug naïve patients with first-episode major depression: An exploratory study in the "real world" everyday clinical practice. <i>Microbial Biotechnology</i> , 2020, 14, 336-342.	1.7	30
32	Alexithymia, suicide ideation, affective temperaments and homocysteine levels in drug naïve patients with post-traumatic stress disorder: an exploratory study in the everyday "real world" clinical practice. <i>International Journal of Psychiatry in Clinical Practice</i> , 2020, 24, 83-87.	2.4	36
33	Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 471,839 people. <i>Lancet Psychiatry</i> , 2020, 7, 52-63.	7.4	109
34	Preclinical Considerations about Affective Disorders and Pain: A Broadly Intertwined, yet Often Under-Explored, Relationship Having Major Clinical Implications. <i>Medicina (Lithuania)</i> , 2020, 56, 504.	2.0	3
35	Environmental risk factors, protective factors, and peripheral biomarkers for ADHD: an umbrella review. <i>Lancet Psychiatry</i> , 2020, 7, 955-970.	7.4	103
36	Editorial: "No Words for Feelings, Yet!" Exploring Alexithymia, Disorder of Affect Regulation, and the "Mind-Body" Connection. <i>Frontiers in Psychiatry</i> , 2020, 11, 593462.	2.6	11

#	ARTICLE	IF	CITATIONS
37	The concept and management of acute episodes of treatment-resistant bipolar disorder: a systematic review and exploratory meta-analysis of randomized controlled trials. <i>Journal of Affective Disorders</i> , 2020, 276, 970-983.	4.1	43
38	Emotional Dysregulation in Adolescents: Implications for the Development of Severe Psychiatric Disorders, Substance Abuse, and Suicidal Ideation and Behaviors. <i>Brain Sciences</i> , 2020, 10, 591.	2.3	38
39	Religious Coping, Hopelessness, and Suicide Ideation in Subjects with First-Episode Major Depression: An Exploratory Study in the Real World Clinical Practice. <i>Brain Sciences</i> , 2020, 10, 912.	2.3	19
40	Overcoming the Use of Mechanical Restraints in Psychiatry: A New Challenge in the Everyday Clinical Practice at the Time of COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 3774.	2.4	4
41	The shocking attitude toward electroconvulsive therapy in Italy. <i>CNS Spectrums</i> , 2020, , 1-3.	1.2	6
42	Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders. <i>Translational Psychiatry</i> , 2020, 10, 152.	4.8	102
43	Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. <i>World Psychiatry</i> , 2020, 19, 214-232.	10.4	167
44	The "dead man walking"™ disorder: an update on Cotard's™ syndrome. <i>International Review of Psychiatry</i> , 2020, 32, 500-509.	2.8	12
45	Predictors of Treatment Resistance Across Different Clinical Subtypes of Depression: Comparison of Unipolar vs. Bipolar Cases. <i>Frontiers in Psychiatry</i> , 2020, 11, 438.	2.6	7
46	Earthquakes, economic crisis and, now, COVID-19: the cry of yell of Central Italy.. <i>Psychiatry Research</i> , 2020, 291, 113181.	3.3	4
47	Prominent autistic traits and subthreshold bipolar/mixed features of depression in severe anorexia nervosa. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 153-161.	1.7	5
48	Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 317-321.	1.7	14
49	An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 554-584.	2.1	25
50	Mediterranean Diet and its Benefits on Health and Mental Health: A Literature Review. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2020, 16, 156-164.	1.2	70
51	Understanding the Complex of Suicide in Depression: from Research to Clinics. <i>Psychiatry Investigation</i> , 2020, 17, 207-221.	1.6	186
52	Brexipiprazole for treatment-resistant major depressive disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1925-1933.	1.8	27
53	Psychometric properties of the Patient Health Questionnaire nine-item version (PHQ-9) for use among hospitalized non-psychiatric medical patients. <i>General Hospital Psychiatry</i> , 2019, 61, 69-75.	2.4	8
54	Association of Antidepressant Use With Adverse Health Outcomes. <i>JAMA Psychiatry</i> , 2019, 76, 1241.	11.0	143

#	ARTICLE	IF	CITATIONS
55	The FDA “Black Box” Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits?. <i>Frontiers in Psychiatry</i> , 2019, 10, 294.	2.6	50
56	The Relationship between Dietary Vitamin K and Depressive Symptoms in Late Adulthood: A Cross-Sectional Analysis from a Large Cohort Study. <i>Nutrients</i> , 2019, 11, 787.	4.1	19
57	Reply to Dr. Sharma’s “Understanding antidepressant tachyphylaxis”. <i>Pharmacological Research</i> , 2019, 141, 620.	7.1	1
58	Reply to Dr. Gentili’s “Analysis of tolerance to antidepressant drugs in FDA Adverse Event Reporting System”. <i>Pharmacological Research</i> , 2019, 141, 618.	7.1	1
59	When Clozapine Fails: Augmentation Strategies in the Management of Clozapine-Resistant Schizophrenia. , 2019, , 349-367.		3
60	The emergence of loss of efficacy during antidepressant drug treatment for major depressive disorder: An integrative review of evidence, mechanisms, and clinical implications. <i>Pharmacological Research</i> , 2019, 139, 494-502.	7.1	42
61	Choosing the appropriate pharmacotherapy for obsessive-compulsive disorder in adult patients with comorbid anxiety disorders: clinical and nosological considerations. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 123-126.	1.8	2
62	Differentiating between bipolar and unipolar depression in functional and structural MRI studies. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 91, 20-27.	4.8	144
63	Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System. <i>Current Pharmaceutical Design</i> , 2019, 25, 381-387.	1.9	33
64	Alexithymia, Suicide Ideation and Homocysteine Levels in Drug Naïve Patients with Major Depression: A Study in the “Real World” Clinical Practice. <i>Clinical Psychopharmacology and Neuroscience</i> , 2019, 17, 318-322.	2.0	29
65	Takotsubo Syndrome and Electroconvulsive Therapy: Time for Rigorous Assessment. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2019, 15, 99-100.	1.2	0
66	Clinical and psychopathological features associated with treatment-emergent mania in bipolar-II depressed outpatients exposed to antidepressants. <i>Journal of Affective Disorders</i> , 2018, 234, 131-138.	4.1	16
67	Comparison of familial and non-familial suicidal behaviors among people with major depressive disorder: Testing the discriminative predicting role of high-yield clinical variables. <i>Journal of Psychiatric Research</i> , 2018, 102, 118-122.	3.1	3
68	The relationship between the dietary inflammatory index (DII®) and incident depressive symptoms: A longitudinal cohort study. <i>Journal of Affective Disorders</i> , 2018, 235, 39-44.	4.1	50
69	Incidence, prevalence and clinical correlates of antidepressant-emergent mania in bipolar depression: a systematic review and meta-analysis. <i>Bipolar Disorders</i> , 2018, 20, 195-227.	1.9	60
70	Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. <i>Therapeutic Advances in Drug Safety</i> , 2018, 9, 237-256.	2.4	130
71	Progress in bipolar disorder drug design toward the development of novel therapeutic targets: a clinician’s perspective. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 221-228.	5.0	12
72	Atypical Antipsychotics in Major Depressive Disorder. , 2018, , 257-268.		2

#	ARTICLE	IF	CITATIONS
73	Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis. <i>Schizophrenia Bulletin</i> , 2018, 44, 1133-1150.	4.3	99
74	Predictors of hospitalization length of stay among re-admitted treatment-resistant Bipolar Disorder inpatients. <i>Journal of Affective Disorders</i> , 2018, 228, 118-124.	4.1	8
75	Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2888.	4.1	137
76	Pharmacological management of depression in patients with multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1533-1540.	1.8	13
77	The identification of biomarkers predicting acute and maintenance lithium treatment response in bipolar disorder: A plea for further research attention. <i>Psychiatry Research</i> , 2018, 269, 658-672.	3.3	21
78	Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review. <i>Current Neuropharmacology</i> , 2018, 16, 583-606.	2.9	72
79	Clozapine-related Sudden Pericarditis in a Patient Taking Long Acting Aripiprazole and Valproate: A Case Report. <i>Clinical Psychopharmacology and Neuroscience</i> , 2018, 16, 505-507.	2.0	11
80	Alexithymia, Suicide Ideation, C-Reactive Protein, and Serum Lipid Levels Among Outpatients with Generalized Anxiety Disorder. <i>Archives of Suicide Research</i> , 2017, 21, 100-112.	2.3	46
81	Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. <i>World Psychiatry</i> , 2017, 16, 163-180.	10.4	1,082
82	Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practice. <i>CNS Spectrums</i> , 2017, 22, 342-347.	1.2	43
83	Depression and pain: primary data and meta-analysis among 237,952 people across 47 low- and middle-income countries. <i>Psychological Medicine</i> , 2017, 47, 2906-2917.	4.5	70
84	The burden of mood-disorder/cerebrovascular disease comorbidity: essential neurobiology, psychopharmacology, and physical activity interventions. <i>International Review of Psychiatry</i> , 2017, 29, 425-435.	2.8	31
85	Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 79, 289-301.	4.8	25
86	Alexithymia and Suicide Risk in Psychiatric Disorders: A Mini-Review. <i>Frontiers in Psychiatry</i> , 2017, 8, 148.	2.6	118
87	Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 757-777.	2.0	286
88	Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions. <i>International Journal of Molecular Sciences</i> , 2017, 18, 135.	4.1	57
89	The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical Review. <i>International Journal of Molecular Sciences</i> , 2017, 18, 349.	4.1	30
90	Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews. <i>BioMed Research International</i> , 2017, 2017, 1-17.	1.9	23

#	ARTICLE	IF	CITATIONS
91	A bibliometric analysis of scientific production on atypical antipsychotic drugs from Italy. Rivista Di Psichiatria, 2017, 52, 236-246.	0.6	3
92	Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine. CNS and Neurological Disorders - Drug Targets, 2017, 16, 65-92.	1.4	25
93	Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review. Neuropsychiatric Disease and Treatment, 2016, 12, 719.	2.2	74
94	Does the "Silver Bullet" Lose its Shine Over the Time? Assessment of Loss of Lithium Response in a Preliminary Sample of Bipolar Disorder Outpatients. Clinical Practice and Epidemiology in Mental Health, 2016, 12, 142-157.	1.2	12
95	Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials. Mediators of Inflammation, 2016, 2016, 1-8.	3.0	30
96	The Interface between Neuroscience and Neuro-Psychoanalysis: Focus on Brain Connectivity. Frontiers in Human Neuroscience, 2016, 10, 20.	2.0	18
97	Atypical Antipsychotics in the Treatment of Acute Bipolar Depression with Mixed Features: A Systematic Review and Exploratory Meta-Analysis of Placebo-Controlled Clinical Trials. International Journal of Molecular Sciences, 2016, 17, 241.	4.1	43
98	Suicide during Perinatal Period: Epidemiology, Risk Factors, and Clinical Correlates. Frontiers in Psychiatry, 2016, 7, 138.	2.6	115
99	The association between smoking prevalence and eating disorders: a systematic review and meta-analysis. Addiction, 2016, 111, 1914-1922.	3.3	65
100	New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Expert Review of Neurotherapeutics, 2016, 16, 483-495.	2.8	18
101	Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives. Expert Opinion on Investigational Drugs, 2016, 25, 719-728.	4.1	35
102	Melatonergic Antidepressant Agomelatine and Its Efficacy in Depressive Disorders. , 2016, , 219-228.		1
103	Melatonin, Sleep, Circadian Rhythm, and Mood Disorders. , 2016, , 117-127.		1
104	Experimental drugs for bipolar psychosis. Expert Opinion on Investigational Drugs, 2016, 25, 1371-1375.	4.1	10
105	Inflammatory markers and suicidal attempts in depressed patients: A review. International Journal of Immunopathology and Pharmacology, 2016, 29, 583-594.	2.1	27
106	An update of safety of clinically used atypical antipsychotics. Expert Opinion on Drug Safety, 2016, 15, 1329-1347.	2.4	112
107	Is there cardiac risk in panic disorder? An updated systematic review. Journal of Affective Disorders, 2016, 194, 38-49.	4.1	24
108	A comparative meta-analysis of TEMPS scores across mood disorder patients, their first-degree relatives, healthy controls, and other psychiatric disorders. Journal of Affective Disorders, 2016, 196, 32-46.	4.1	69



#	ARTICLE	IF	CITATIONS
109	How common is bipolar disorder in general primary care attendees? A systematic review and meta-analysis investigating prevalence determined according to structured clinical assessments. Australian and New Zealand Journal of Psychiatry, 2016, 50, 631-639.	2.3	29
110	The prevalence and predictors of bipolar and borderline personality disorders comorbidity: Systematic review and meta-analysis. Journal of Affective Disorders, 2016, 195, 105-118.	4.1	92
111	The prevalence and predictors of obstructive sleep apnea in major depressive disorder, bipolar disorder and schizophrenia: A systematic review and meta-analysis. Journal of Affective Disorders, 2016, 197, 259-267.	4.1	120
112	The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders. Current Pharmaceutical Design, 2016, 22, 5144-5162.	1.9	25
113	Psychological perspective of medication adherence in transplantation. World Journal of Transplantation, 2016, 6, 736.	1.6	10
114	BDNF plasma levels variations in major depressed patients receiving duloxetine. Neurological Sciences, 2015, 36, 729-734.	1.9	19
115	Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression. International Journal of Molecular Sciences, 2015, 16, 1111-1130.	4.1	66
116	Factor structure and reliability of the Arabic adaptation of the Hypomania Check List-32, second revision (HCL-32-R2). Comprehensive Psychiatry, 2015, 59, 141-150.	3.1	14
117	Alexithymia, responsibility attitudes and suicide ideation among outpatients with obsessive-compulsive disorder: An exploratory study. Comprehensive Psychiatry, 2015, 58, 82-87.	3.1	36
118	A meta-analysis investigating the prevalence and moderators of migraines among people with bipolar disorder. Journal of Affective Disorders, 2015, 178, 88-97.	4.1	38
119	Factor structure and reliability of the Italian adaptation of the Hypomania Check List-32, second revision (HCL-32-R2). Journal of Affective Disorders, 2015, 178, 112-120.	4.1	14
120	Cognitive tolerability following successful long term treatment of major depression and anxiety disorders with SSRI antidepressants. Journal of Affective Disorders, 2015, 173, 211-215.	4.1	41
121	Prevalence and clinical features associated to bipolar disorder and migraine comorbidity: a systematic review. Comprehensive Psychiatry, 2015, 56, 1-16.	3.1	20
122	Cotard's Syndrome after breast surgery successfully treated with aripiprazole augmentation of escitalopram: a case report. Rivista Di Psichiatria, 2015, 50, 95-8.	0.6	7
123	Targeting the Noradrenergic System in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis of Prazosin Trials. Current Drug Targets, 2015, 16, 1094-1106.	2.1	89
124	Treatment of Antipsychotic-Induced Hyperprolactinemia: An Update on the Role of the Dopaminergic Receptors D2 Partial Agonist Aripiprazole. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2014, 8, 30-37.	0.6	24
125	Cognitive functioning and subjective quality of life in relapsing-remitting multiple sclerosis patients before and after percutaneous transluminal angioplasty: a preliminary report. Neuropsychiatric Disease and Treatment, 2014, 10, 1039.	2.2	4
126	Electroretinographic modifications induced by agomelatine: a novel avenue to the understanding of the claimed antidepressant effect of the drug?. Neuropsychiatric Disease and Treatment, 2014, 10, 907.	2.2	13



#	ARTICLE	IF	CITATIONS
127	Obsessive-Compulsive Aspects and Pathological Gambling in an Italian Sample. <i>BioMed Research International</i> , 2014, 2014, 1-10.	1.9	14
128	A $\beta$ 1-42 monomers or oligomers have different effects on autophagy and apoptosis. <i>Autophagy</i> , 2014, 10, 1827-1843.	9.1	70
129	Emerging Mania Following Escitalopram Withdrawal in a Patient with Unipolar Depression Managed with its Reintroduction. <i>Journal of Psychiatric Practice</i> , 2014, 20, 228-231.	0.7	9
130	Successful Use of Agomelatine in the Treatment of Major Depression in a Woman Taking Tamoxifen. <i>Clinical Neuropharmacology</i> , 2014, 37, 31-33.	0.7	5
131	Somatopsychic Correlates and Quality of Life of the Dialyzed Patient: A Cross-Sectional Study. <i>Transplantation Proceedings</i> , 2014, 46, 2199-2202.	0.6	7
132	Duloxetine-bupropion combination for treatment-resistant atypical depression: A double-blind, randomized, placebo-controlled trial. <i>European Neuropsychopharmacology</i> , 2014, 24, 1269-1278.	0.7	14
133	Clozapine-Related Pericarditis During Titration Phase in a Patient With Resistant Schizophrenia and Concomitant Valproate Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 649-651.	1.4	8
134	The Role of Agomelatine in the Treatment of Anxiety Disorders. , 2014, , 297-305.		1
135	Cotard's Syndrome: Clinical Case Presentation and Literature Review. <i>International Neuropsychiatric Disease Journal</i> , 2014, 2, 348-355.	0.1	2
136	NGF serum levels variations in major depressed patients receiving duloxetine. <i>Psychoneuroendocrinology</i> , 2013, 38, 1824-1828.	2.7	45
137	Sensation seeking in major depressive patients: Relationship to sub-threshold bipolarity and cyclothymic temperament. <i>Journal of Affective Disorders</i> , 2013, 148, 375-383.	4.1	27
138	Treatment adherence towards prescribed medications in bipolar-II acute depressed patients: Relationship with cyclothymic temperament and "therapeutic sensation seeking" in response towards subjective intolerance to pain. <i>Journal of Affective Disorders</i> , 2013, 151, 596-604.	4.1	39
139	Agomelatine Treatment of Major Depressive Disorder in Parkinson's Disease: A Case Series. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2013, 25, 343-345.	1.8	16
140	The relationship between drive to thinness, conscientiousness and bulimic traits during adolescence: a comparison between younger and older cases in 608 healthy volunteers. <i>Annals of General Psychiatry</i> , 2013, 12, 34.	2.7	4
141	Affective temperaments are associated with specific clusters of symptoms and psychopathology: A cross-sectional study on bipolar disorder inpatients in acute manic, mixed, or depressive relapse. <i>Journal of Affective Disorders</i> , 2013, 151, 540-550.	4.1	46
142	VEGF plasma level variations in duloxetine-treated patients with major depression. <i>Journal of Affective Disorders</i> , 2013, 151, 590-595.	4.1	32
143	Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds. <i>Journal of Affective Disorders</i> , 2013, 145, 300-307.	4.1	49
144	Agomelatine reversal of escitalopram-induced apathy: A case report. <i>Psychiatry and Clinical Neurosciences</i> , 2013, 67, 190-191.	1.8	9

#	ARTICLE	IF	CITATIONS
145	Is There a Role for Agomelatine in the Treatment of Anxiety Disorders? A Review of Published Data. International Journal of Immunopathology and Pharmacology, 2013, 26, 299-304.	2.1	22
146	The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice. International Journal of Molecular Sciences, 2013, 14, 12458-12483.	4.1	66
147	Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study. Neuropsychiatric Disease and Treatment, 2013, 9, 243.	2.2	53
148	Efficacy and Safety of Long Acting Injectable Atypical Antipsychotics: A Review. Current Clinical Pharmacology, 2013, 8, 256-264.	0.6	25
149	The Role of Intranasal Oxytocin in the Treatment of Patients with Schizophrenia: A Systematic Review. CNS and Neurological Disorders - Drug Targets, 2013, 12, 252-264.	1.4	32
150	Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance. Current Neuropharmacology, 2012, 10, 97-123.	2.9	85
151	Discriminative Hypomania Checklist-32 Factors in Unipolar and Bipolar Major Depressive Patients. Psychopathology, 2012, 45, 390-398.	1.5	18
152	Different measures of impulsivity in patients with anxiety disorders: A case control study. Psychiatry Research, 2012, 197, 231-236.	3.3	42
153	The argument of antidepressant drugs in the treatment of bipolar depression: mixed evidence or mixed states?. Expert Opinion on Pharmacotherapy, 2012, 13, 2037-2051.	1.8	30
154	Aβ <sub>1-42</sub> induces physiological transcriptional regulation of BACE1. Journal of Neurochemistry, 2012, 122, 1023-1031.	3.9	22
155	Aβ <sub>1-42</sub> -mediated down-regulation of Uchl1 is dependent on NF-κB activation and impaired BACE1 lysosomal degradation. Aging Cell, 2012, 11, 834-844.	6.7	57
156	Comments on: "Socio-economic factors and suicide rates in European Union countries". Legal Medicine, 2012, 14, 278.	1.3	0
157	A case of deep venous thrombosis following protracted catatonic immobility recovered with electroconvulsive therapy: the relevance for an early intervention. General Hospital Psychiatry, 2012, 34, 209.e5-209.e7.	2.4	17
158	A case of severe oral self-injurious Tourette's syndrome alleviated by pregabalin. General Hospital Psychiatry, 2012, 34, 321.e1-321.e4.	2.4	6
159	The influence of affective temperaments and psychopathological traits on the definition of bipolar disorder subtypes: A study on Bipolar I Italian National sample. Journal of Affective Disorders, 2012, 136, e41-e49.	4.1	98
160	Unexplained Somatic Symptoms during Major Depression: Prevalence and Clinical Impact in a National Sample of Italian Psychiatric Outpatients. Psychopathology, 2011, 44, 116-124.	1.5	25
161	Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series. Annals of General Psychiatry, 2011, 10, 5.	2.7	38
162	Agomelatine in the treatment of panic disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 286-287.	4.8	14

#	ARTICLE	IF	CITATIONS
163	Prevalence and diagnostic distribution of medically unexplained painful somatic symptoms across 571 major depressed outpatients. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 217.	2.2	10
164	Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 51.	2.2	36
165	Amyloid- $\beta$ 42 Activates the Expression of BACE1 Through the JNK Pathway. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 871-883.	2.6	55
166	Impulsivity in anxiety disorder patients: Is it related to comorbid cyclothymia?. <i>Journal of Affective Disorders</i> , 2011, 133, 600-606.	4.1	31
167	Electroretinographic assessment in major depressed patients receiving duloxetine: Might differences between responders and non-responders indicate a differential biological background?. <i>Journal of Affective Disorders</i> , 2011, 135, 154-159.	4.1	26
168	An open pilot study of zonisamide augmentation in major depressive patients not responding to a low dose trial with duloxetine: preliminary results on tolerability and clinical effects. <i>Annals of General Psychiatry</i> , 2011, 10, 23.	2.7	5
169	Catatonia: A Narrative Review. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2011, 11, 73-79.	1.1	17
170	Are atypical depression, borderline personality disorder and bipolar II disorder overlapping manifestations of a common cyclothymic diathesis?. <i>World Psychiatry</i> , 2011, 10, 45-51.	10.4	97
171	Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2817-2831.	1.8	17
172	A Systematic, Updated Review on the Antidepressant Agomelatine Focusing on its Melatonergic Modulation. <i>Current Neuropharmacology</i> , 2010, 8, 287-304.	2.9	103
173	Lifetime co-morbidity with different subtypes of eating disorders in 148 females with bipolar disorders. <i>Journal of Affective Disorders</i> , 2010, 121, 147-151.	4.1	48
174	Adding 5-hydroxytryptamine receptor type 3 antagonists may reduce drug-induced nausea in poor insight obsessive-compulsive patients taking off-label doses of selective serotonin reuptake inhibitors: a 52-week follow-up case report. <i>Annals of General Psychiatry</i> , 2010, 9, 39.	2.7	5
175	Current Nosology of Treatment Resistant Depression: A Controversy Resistant to Revision. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2010, 6, 20-24.	1.2	32
176	Obsessive-compulsive disorder with bipolar diathesis following isotretinoin therapy remitting upon treatment with olanzapine and fluvoxamine. <i>Neuropsychiatric Disease and Treatment</i> , 2010, 6, 719.	2.2	7
177	Tinnitus psychopharmacology: A comprehensive review of its pathomechanisms and management. <i>Neuropsychiatric Disease and Treatment</i> , 2010, 6, 209.	2.2	33
178	Diagnosis of co-morbid axis-I psychiatric disorders among women with newly diagnosed, untreated endocrine disorders. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 991-996.	2.6	14
179	Upregulation of Presenilin 1 in Brains of Sporadic, Late-Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 771-775.	2.6	19
180	A Case of Treatment Resistant Depression and Alcohol Abuse in a Person with Mental Retardation: Response to Aripiprazole and Fluvoxamine Therapy upon Consideration of a Bipolar Diathesis after Repetitive Failure to Respond to Multiple Antidepressant Trials. <i>Case Reports in Medicine</i> , 2010, 2010, 1-5.	0.7	1

#	ARTICLE	IF	CITATIONS
181	The impact of premenstrual dysphoric disorder among 92 bipolar patients. European Psychiatry, 2010, 25, 450-454.	0.2	28
182	Current Nosology of Treatment Resistant Depression: A Controversy Resistant to Revision. Clinical Practice and Epidemiology in Mental Health, 2010, 1, 20-24.	1.2	2
183	Amyloid- $\beta$ 242 Plasma Levels are Elevated in Amnesic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2009, 18, 267-271.	2.6	22
184	Obsessive-compulsive disorder and related disorders: a comprehensive survey. Annals of General Psychiatry, 2009, 8, 13.	2.7	30
185	Medicine and psychiatry in Western culture: Ancient Greek myths and modern prejudices. Annals of General Psychiatry, 2009, 8, 21.	2.7	18
186	Medicine and psychiatry in Western culture: among Ancient Greek myths and modern prejudices. Medicina Nei Secoli, 2009, 21, 1105-22.	0.1	0
187	Epileptic Seizures but not Pseudoseizures are Associated with Decreased Density of the Serotonin Transporter in Blood Platelet Membranes. Neurochemical Research, 2008, 33, 2263-2268.	3.3	8
188	Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report. Annals of General Psychiatry, 2008, 7, 26.	2.7	10